Tofacitinib is known to be an effective inhibitor of the JAK–STAT pathway and is used to inhibit the production of many pro-inflammatory cytokines that are enhanced in RA patients [24,33,34]. The gene discussed is SOAT1; the disease is rheumatoid arthritis.